Leerink Partners Reiterates Buy Rating on SAB Biotherapeutics
Leerink Partners maintains its buy rating on SAB Biotherapeutics with a $12 price target, a 210.88% upside from the current price.
Key Points
- Leerink Partners reiterated its buy rating for SAB Biotherapeutics, setting a $12 price target as of June 15, 2026.
- Leerink Partners's $12 price target implies 210.88% upside from SAB Biotherapeutics, Inc.'s ($SABS) current $3.86 share price.
- SAB Biotherapeutics, trading at $3.33, has a market cap of $298.2 million and a 52-week range between $1.65 and $6.60.
- Recent insider activity includes significant purchases by the CEO and CFO, while analysts maintain a strong buy consensus.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, Leerink Partners reiterated its buy rating for SAB Biotherapeutics, Inc. (NasdaqCM:SABS), maintaining a price target of $12. Analyst Thomas Smith believes in the long-term potential of the biotech company, which focuses on developing polyclonal immunotherapeutic antibodies.
Other Institutional Activity in SAB Biotherapeutics
VIVO CAPITAL, LLC maintained its position in SAB Biotherapeutics with 11,420,000 shares valued at approximately $43.7 million. CALIGAN PARTNERS LP added 7,967,207 shares, bringing its total to the same amount, valued at about $30.5 million. PERCEPTIVE ADVISORS LLC significantly increased its holdings by 5,628,533 shares, reaching a total of 6,431,743 shares worth around $24.6 million. RA CAPITAL MANAGEMENT, L.P. held steady with 4,401,500 shares valued at $16.9 million, and COMMODORE CAPITAL LP matched this holding.
SAB Biotherapeutics, Inc. Stock Up 1.8%
Shares of NasdaqCM:SABS traded at $3.33. SAB Biotherapeutics has a market cap of approximately $298.2 million. The company's forward P/E ratio is not meaningful as it is currently unprofitable. The stock's 52-week low is $1.65, while its high is $6.60. It has a 50-day moving average of $3.69 and a 200-day moving average of $3.48. The company shows strong liquidity with a current ratio of 11.45 and a quick ratio of 11.06, alongside a debt-to-equity ratio of 2.72.
$SABS price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
SAB Biotherapeutics is gearing up for its next earnings report on August 11, 2026. The company is currently in a clinical-stage with no significant revenue, showing a net margin of 0% and a negative return on equity of -0.32%.
Insider Buying and Selling at SAB Biotherapeutics, Inc.
Recent insider transactions include CEO Samuel Reich buying 4,800,000 shares on February 3, 2026. On the same day, CFO Lucy To and COO Christoph Lawrence each purchased 2,400,000 shares. Additionally, Chief Medical Officer Alexandra Kropotova acquired 2,400,000 shares. These transactions suggest confidence in the company's future.
Analysts Set New Price Targets
On June 15, 2026, HC Wainwright & Co. reiterated its buy rating for SAB Biotherapeutics with a $10 price target. Citigroup initiated coverage with a buy rating and an $11 target on May 22, 2026. Jefferies also initiated a buy rating with an $11 target on May 20, 2026. The consensus among analysts remains strong buy, with an average target price of $10.6 based on 10 opinions.
About SAB Biotherapeutics
SAB Biotherapeutics, Inc. is a biotechnology company based in Miami Beach, Florida. Founded in 2014, it focuses on developing human polyclonal immunotherapeutic antibodies to treat immune system disorders and infectious diseases. Its lead product, SAB-142, is in Phase 2b clinical trials for autoimmune type 1 diabetes. The company is led by CEO Samuel J. Reich and employs 86 people.
Bottom Line
Leerink Partners' reaffirmation of a buy rating with a $12 target reflects confidence in SAB Biotherapeutics' potential. With strong insider purchases and a positive analyst consensus, the company's focus on innovative treatments in biotechnology continues to attract attention. Investors should note that 13F filings and analyst ratings are backward-looking and may not indicate current positions or future performance.
Get SAB Biotherapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SABS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.